What happens when you stop taking GLP-1s? Plus, the DTC pharma ad crackdown begins.

If there are two topics medical marketers can’t get enough of, it’s GLP-1s and the ongoing crackdown on DTC pharma ads. 

This week’s episode of the MM+M Podcast delves into what happens when patients stop taking GLP-1s as well as how the first week of the Trump administration’s enhanced enforcement of restrictions on DTC pharma ads has gone.

To start the episode, reporter Heerea Rikhraj brings us a conversation with Dr. Innocent Clement, CEO and founder of CIBA Health, about what happens after people stop taking these powerful, life-changing drugs as well as what medical marketers can do to fill the gap for education.

And for our Trends segment, we analyze the Trump administration’s proposed crackdown on DTC pharma ads and how an ad for AstraZeneca’s at-home flu vaccine led to a warning letter from the FDA. 

Music: “Deep Reflection” by DP and Triple Scoop Music.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.